Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo

Documenti analoghi

• Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy
  di: Saran, Frank, et al.
  Pubblicazione: (2016)
• Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma
  di: Wick, Wolfgang, et al.
  Pubblicazione: (2016)
• Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio
  di: Chinot, Olivier L., et al.
  Pubblicazione: (2016)
• AT-17 RE-ANALYSIS OF PFS/RESPONSE USING ORIGINAL MACDONALD CRITERIA AND RESPONSE EVALUATION CRITERIA IN SOLID TUMORS IN THE PHASE III AVAGLIO STUDY OF BEVACIZUMAB PLUS RADIOTHERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA
  di: Chinot, Olivier L., et al.
  Pubblicazione: (2014)
• AT-18 SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])
  di: Cloughesy, Tim, et al.
  Pubblicazione: (2014)